Starling Oncology Inc provides oncology care services in community settings... Show more
Starling Oncology, formerly The Oncology Institute, is one of the largest value-based oncology groups in the United States, operating more than 100 clinics across five states. The company's third quarter 2026 report, covering the three months ended September 30, 2026, marks its first full quarter under the new STLN ticker following an August 2026 rebrand. The results matter because they test the durability of Starling's growth engine, particularly its specialty pharmacy segment and its capitated (fixed per-patient payment) care model. Investors are also watching the company's path toward profitability, as management has emphasized adjusted EBITDA positivity and improving free cash flow as key milestones in a competitive, capital-intensive oncology market.
Starling Oncology reported total revenue of $169.8 million for the third quarter of 2026, up 24.3% from $136.6 million in the prior-year period and modestly above consensus estimates. Patient services revenue, which includes both capitated and fee-for-service arrangements, was $60.0 million, or 35.4% of total revenue. Within that segment, capitated revenue rose 39.5% year over year to $28.7 million, while fee-for-service revenue declined 21% to $31.3 million, partly reflecting contract changes that replaced certain drug carve-outs with per-member-per-month rate adjustments.
Specialty pharmacy was the standout, generating $109.3 million in revenue, up 44% year over year, with gross margin of 24.2%. Total gross profit climbed to $30.7 million from $18.9 million, and overall gross margin expanded to 18.1% from 13.9%. The company posted a net loss of $15.7 million, or $0.13 per share, compared with a loss of $16.5 million, or $0.14 per share, a year earlier. Adjusted EBITDA reached $3.4 million, exceeding management's third-quarter outlook of $0.5 million to $1.5 million. The MLR for capitated contracts rose to 81.0% from 67.8% a year ago, while nine-month free cash flow swung to positive $20.2 million from negative $26.9 million.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping investors monitor names like Starling Oncology (STLN) alongside broader market trends. Consider exploring the AI Screener to refine your research workflow.
Sentiment heading into the report reflected optimism around Starling's rapid revenue growth and improving profitability, with shares having risen sharply year to date. The post-earnings reaction has been more measured, as a top-and-bottom-line split framed the narrative. While revenue beat expectations and adjusted EBITDA came in above guidance, the wider-than-expected per-share loss and a trimmed top end of full-year revenue guidance introduced caution. The elevated MLR and management's expectation of an 85–90% range in 2027 as new patients are onboarded also weighed on the capitated segment outlook, balancing investor enthusiasm about pharmacy momentum against near-term profitability concerns.
Starling affirmed its full-year 2026 framework while making several adjustments. The company narrowed its adjusted EBITDA outlook to $4–$6 million and lowered the top end of its revenue range to $650–$660 million, while raising the low end of its gross profit guidance. It also guided fourth-quarter adjusted EBITDA to $3–$5 million and now expects full-year free cash flow of $5–$10 million.
Looking ahead, investors should watch how specialty pharmacy margins normalize. Management flagged that some favorable rebates and drug-price movements are unlikely to recur, projecting pharmacy gross margin in the high teens going forward. A second key factor is the Inflation Reduction Act, which the company says will affect an additional number of oral drugs in 2027 but is expected to have a limited impact on revenue and margins.
Finally, the onboarding of new capitated patients, including a newly entered state, is expected to push the Medical Loss Ratio higher in 2027, a near-term profitability consideration that will be closely monitored against the company's stated goal of sustained adjusted EBITDA positivity and continued growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry HospitalNursingManagement